Trial Profile
Phase II Study of Combination of Hyper-CVAD and Dasatinib (NSC-732517) With or Without Allogeneic Stem Cell Transplant in Patients With Philadelphia (Ph) Chromosome Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL) (A BMT Study)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 15 Feb 2024
Price :
$35
*
At a glance
- Drugs Dasatinib (Primary) ; Cyclophosphamide; Cytarabine; Cytarabine; Dexamethasone; Dexamethasone; Doxorubicin; Etoposide; Filgrastim; Folinic acid; Immunosuppressants; Mesna; Methotrexate; Methotrexate; Methylprednisolone; Prednisone; Sirolimus; Tacrolimus; Tacrolimus; Vincristine
- Indications Graft-versus-host disease; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Therapeutic Use
- Acronyms BMT
- 19 Feb 2024 Planned End Date changed from 6 Jan 2024 to 6 Jan 2025.
- 07 Feb 2023 Planned End Date changed from 6 Jan 2023 to 6 Jan 2024.
- 07 Jan 2022 Planned End Date changed from 24 Sep 2019 to 6 Jan 2023.